Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIFA: Targeting Insulin Feedback to Enhance Alpelisib in Metastatic Breast Cancer
NCT05090358Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2021
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of canagliflozin in hyperglycemia, sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2021; status: active, not recruiting.
02
Drugs
canagliflozin
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on NCT05090358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05090358.